We collaborate with the world’s leading pharma, biotech and academic organisations to lower the risks and time frames in disease research and preclinical drug discovery

Euretos provides a unique combination of predictive computational disease models and direct access to our AI-integrated knowledge base of biomolecular databases, literature and patents to evaluate predictions and findings. This empowers scientists to draw their own, evidence based, conclusions and develop data-driven insights into human disease biology.

Our ready-to-use applications and capabilities enable taking a data-driven approach to:

Target Discovery – Novel target predictions to improve preclinical pipeline performance in all therapeutic areas

Indication Selection – Novel disease association predictions to expand indications of existing drugs

Target Evaluation – Accelerate assessment of target candidates from in-house discovery and in-licensing